Comparison of Terbinafine and Itraconazole in patients of tinea cruris
Completed
- Conditions
- Diseases of the skin and subcutaneous tissue, (2) ICD-10 Condition: L00-L99||Diseases of the skin and subcutaneous tissue,
- Registration Number
- CTRI/2023/05/052604
- Lead Sponsor
- AGMC GBP Hospital
- Brief Summary
Positive KOH Tinea cruris patients will be randomized and recruited into two groups and oral Terbinafine 500 mg and oral Itraconazole 100 mg will be given for 14 days. The purpose of the study is to compare the safety and efficiency of Terbinafine and Itraconazole. For that purpose LFT will be 0 and 42 days and KOH will be done at 0, 14 and 42 days of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 170
Inclusion Criteria
ALL NEWLY DIAGNOSED TINEA CRURIS SUBJECTS HAVE NOT RECEIVED ANTIFUNGAL IN LAST 14 DAYS.
Exclusion Criteria
PREGNANT AND LACTATING WOMEN PATIENTS ON IMMUNOSUPPRESSIVE DRUGS PATIENTS UNWILLING FOR A REGULAR FOLLOW UP PATIENTS WITH RELAPSE AND RECURRENT CASES OF TINEA CRURIS.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Erythema, Scaling, peripheral spread to other body sites After 14 days and 42 days of treatment
- Secondary Outcome Measures
Name Time Method LFT 42 DAYS
Trial Locations
- Locations (1)
Agartala Govt Medical College and GBP hospital
🇮🇳Tripura, TRIPURA, India
Agartala Govt Medical College and GBP hospital🇮🇳Tripura, TRIPURA, IndiaBhargabi KunduPrincipal investigator9774712971bhgabikundu@gmail.com